Investment Screening in France: Protecting Drug and Device Safety Amid Coronavirus Fears
Friday, 11 October 2024, 05:34
Investment Screening and Drug Safety in France
In recent times, coronavirus has reshaped the landscape of investment in France. The French government under Emmanuel Macron aims to tighten investment screening for critical sectors, especially the pharmaceutical industry. Marc Ferracci, a prominent political figure, underscores the need for enhanced protectionism to ensure drug and device safety during this health crisis.
Concerns Over American Investment
- The ongoing negotiations for the sale of Sanofi's subsidiary producing over-the-counter medicines have raised eyebrows.
- French authorities express worries over transferring control to an American private equity fund, CD&R.
- Protection of essential vaccines and medicines from foreign investment is a priority.
The Impact of State Aid
- State aid is crucial for maintaining local drug production.
- Macron's administration aims to bolster the safety standards and infrastructure of the pharmaceutical sector.
- Strengthening local investments in drug safety will be key to countering any potential risks from foreign acquisitions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.